Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20

 Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20

Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20

Shots:

  • The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs
  • With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 ≤1% in 12mos.achieved in 45mg/ day (38.7%), and responses were maintained with 15 mg / day, 75% patients with 45mg & 88% with 30mg were able to maintain BCR- ABL1 ≤1% for up to 2yrs.
  • Iclusig is a kinase inhibitor directed mainly to the protein BCR-ABL1, thus inhibits the activity of BCR-ABL1 and its mutations. The company will utilize these data to file sNDA to the US FDA for the therapy

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Takeda

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post